TransMedics Group, Inc.
TMDX
$68.94
$0.090.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.24% | 37.13% | 41.20% | 48.09% | 64.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.24% | 37.13% | 41.20% | 48.09% | 64.43% |
| Cost of Revenue | 31.47% | 35.23% | 37.92% | 51.56% | 77.26% |
| Gross Profit | 29.41% | 38.43% | 43.45% | 45.85% | 56.70% |
| SG&A Expenses | 16.16% | 9.82% | 17.09% | 24.60% | 36.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.27% | 22.98% | 27.95% | 37.65% | 54.55% |
| Operating Income | 79.82% | 189.59% | 186.82% | 169.55% | 250.24% |
| Income Before Tax | 78.44% | 200.51% | 184.43% | 4,906.22% | 529.61% |
| Income Tax Expenses | -7,514.09% | -26,292.72% | 6,856.25% | 259.87% | 176.41% |
| Earnings from Continuing Operations | 251.23% | 436.58% | 181.16% | 2,288.73% | 580.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 251.23% | 436.58% | 181.16% | 2,288.73% | 580.13% |
| EBIT | 79.82% | 189.59% | 186.82% | 169.55% | 250.24% |
| EBITDA | 69.14% | 134.86% | 135.74% | 134.31% | 183.01% |
| EPS Basic | 244.82% | 421.46% | 173.50% | 2,410.18% | 564.23% |
| Normalized Basic EPS | 75.57% | 193.08% | 160.64% | 134.92% | 178.26% |
| EPS Diluted | 217.37% | 376.19% | 165.89% | 5,763.75% | 494.65% |
| Normalized Diluted EPS | 66.92% | 160.40% | 134.23% | 112.95% | 162.11% |
| Average Basic Shares Outstanding | 2.06% | 2.30% | 2.56% | 2.69% | 2.54% |
| Average Diluted Shares Outstanding | 8.44% | 15.11% | 11.87% | 10.68% | 9.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |